Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: A retrospective cohort study

Critical Care

Volumn 17, Issue 4, 2013, Pages

  Rocco, Monica ^a   Montini, Luca ^b   Alessandri, Elisa ^a   Venditti, Mario ^a   Laderchi, Amalia ^a   De Gennaro, Pascale ^b   Raponi, Giammarco ^a   Vitale, Michela ^a   Pietropaoli, Paolo ^a   Antonelli, Massimo ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; COLIMICINA; COLISTIMETHATE; CREATININE; GENTAMICIN; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; COLISTIN;

ACUTE KIDNEY FAILURE; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEPTIC SHOCK; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; STEADY STATE; TEACHING HOSPITAL; TREATMENT DURATION; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; SEPSIS;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; COLISTIN; CRITICAL ILLNESS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SEPSIS;

EID: 84887197097     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12853     Document Type: Article

References (32)

1. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006, 42:657-668. 10.1086/499819, 16447111.
2. Li J, Nation RL, Milne R, Turnindge J, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005, 25:11-25. 10.1016/j.ijantimicag.2004.10.001, 15620821.
3. Linden PK, Paterson DL. Parenteral and inhaled colistin for the treatment of ventilator-associated pneumonia. Clin Infect Dis 2006, 43(Suppl 2):S89-94.
4. Li J, Rayner CR, Nation RL, Deans A, Boots R, Widdecombe N, Douglas A, Lipman J. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agent Chemother 2005, 49:4814-4815.
5. Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, Rafailidis P, Apostolakos H, Baltopoulos P. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open label, uncontrolled study. Clin Ther 2008, 30:143-151. 10.1016/j.clinthera.2008.01.015, 18343250.
6. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, the Acute Dialysis Quality Initiative workgroup Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-R212. 10.1186/cc2872, 522841, 15312219, the Acute Dialysis Quality Initiative workgroup.
7. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18:268-281. 10.1111/j.1469-0691.2011.03570.x, 21793988.
8. Garzotto F, Piccinni P, Cruz D, Gramaticopolo S, Dal Santo M, Aneloni G, Kim JC, Rocco M, Alessandri E, Giunta F, Michetti V, Iannuzzi M, Belluomo Anello C, Brienza N, Carlini M, Pelaia P, Gabbanelli V, Ronco C, NEFROINT investigation group RIFLE-based data collection/management system applied to a prospective cohort multicenter Italian study on the epidemiology of acute Kidney injury in the intensive care unit. Blood Purif 2011, 31:159-171. 10.1159/000322161, 21228585, NEFROINT investigation group.
9. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presnell JJ, Ayers D, VASST Investigators Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008, 358:877-887. 10.1056/NEJMoa067373, 18305265, VASST Investigators.
10. American Thoracic Society, Infectious Diseases Society of America Guidelines for the management of adults with Hospital acquired, ventilator-associated, and Healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. American Thoracic Society, Infectious Diseases Society of America.
11. Dodek P, Keenan S, Cook D, Heyland D, Jacka M, Hand L, Muscedere J, Foster D, Mehta N, Hall R, Bruin Buisson C, Canadian Critical Care Trials Group, Canadian Critical Care Society Evidence-based clinical practice guidelines for the prevention of ventilator-associated pneumonia. Ann Intern Med 2004, 141:305-313. 10.7326/0003-4819-141-4-200408170-00011, 15313747, Canadian Critical Care Trials Group, Canadian Critical Care Society.
12. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram negative bacteria. Antimicrob Agents Chemother 2009, 53:3430-3436. 10.1128/AAC.01361-08, 2715599, 19433570.
13. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006, 6:589-601. 10.1016/S1473-3099(06)70580-1, 16931410.
14. Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 2007, 46:997-1008. 10.2165/00003088-200746120-00003, 18027987.
15. Pea F, Furlanut M, Negri C, Pavan F, Crapis M, Cristini F, Viale PG. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2009, 53:1863-1867. 10.1128/AAC.01149-08, 2681515, 19223642.
16. Prins JM, Weverling GJ, de Blok K, van Ketel RJ, Speelman P. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 1996, 40:2494-2499. 163563, 8913452.
17. Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012, 54:670-680. 10.1093/cid/cir934, 22322268.
18. Vaara M, Fox J, Loidl G, Siikanen O, Apajalahti J, Hansen F, Frimodt-Moeller N, Nagai J, Takano M, Vaara T. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob Agents Chemother 2008, 52:3229-3236. 10.1128/AAC.00405-08, 2533495, 18591267.
19. Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, Forrest A, Bulitta JB, Tsuji BT. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010, 30:1279-1291. 10.1592/phco.30.12.1279, 21114395.
20. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006, 10:R27. 10.1186/cc3995, 1550802, 16507149.
21. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010, 35:297-300. 10.1016/j.ijantimicag.2009.11.016, 20045293.
22. Kasiakou SK, Michalopulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005, 49:3136-3146. 10.1128/AAC.49.8.3136-3146.2005, 1196256, 16048915.
23. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005, 5:1. 10.1186/1471-2334-5-1, 547910, 15642116.
24. Kim J, Lee K-H, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 2009, 34:434-438. 10.1016/j.ijantimicag.2009.06.028, 19726164.
25. Hartzell JD, Neff R, Ake R, Howard R, Olson S, Paolino K, Vishneopolsky M, Weintrob A, Wortmann G. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009, 48:1724-1728. 10.1086/599225, 19438394.
26. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS. Incidence of and Risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011, 53:879-884. 10.1093/cid/cir611, 21900484.
27. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect 2011, 62:187-190. 10.1016/j.jinf.2010.11.013, 21129401.
28. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010, 54:4503-4505. 10.1128/AAC.01707-09, 2944569, 20660694.
29. Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J. Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol 2008, 19:413-418. 2663472, 19436571.
30. Nation R, Li J. Colistin in the 21th century. Curr Opin Infect Dis 2009, 22:535-543. 10.1097/QCO.0b013e328332e672, 2869076, 19797945.
31. Teixeira C, Garzotto F, Piccinni P, Brienza N, Iannuzzi M, Gramaticopolo S, Forfori F, Pelaia P, Rocco M, Ronco C, Anello CB, Bove T, Carlini M, Michetti V, Pelaia P, Cruz DN, for the NEFROlogiae Cura INTensiva (NEFROINT) investigators Fluid balance and urine volume are independent predictors of mortality in acute kidney injury. Crit Care 2013, 17:R14. 10.1186/cc12484, 23347825, for the NEFROlogiae Cura INTensiva (NEFROINT) investigators.
32. Bagshaw SM, Lapisky S, Dial A Arabi Y, Dodek P, Wood G, Ellis P, Guzman J, Marshall J, Parrillo JE, Skrobik Y, Kumar A, Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med 2009, 35:871-878. 10.1007/s00134-008-1367-2, 19066848, Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group.